Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11043630 | 0.81 | DYRK1A (0.45) | DYRK1APIK3CGPDE10APIK3CAAKT1 | |
| SCHEMBL756100 | 0.73 | KDM4E (0.50) | DYRK1AAHRKDM4EPDE10A | |
| SCHEMBL12664450 | 0.70 | PIK3CG (0.49) | PIK3CGPIK3CACSNK1DCSNK1E | |
| SCHEMBL10277867 | 0.69 | CSNK1D (0.40) | AHRCSNK1DCSNK1E | |
| SCHEMBL3086869 | 0.68 | KDM4E (0.44) | DYRK1AAHRKDM4EPDE10A | |
| SCHEMBL2066344 | 0.68 | PDE10A (0.36) | DYRK1AAHRKDM4EPDE10A | |
| SCHEMBL2066150 | 0.67 | RBP4 (0.44) | DYRK1AAHRKDM4EPDE10A | |
| SCHEMBL3086598 | 0.66 | AHR (0.39) | DYRK1AAHRKDM4EPDE10A | |
| SCHEMBL12909569 | 0.66 | PIK3CG (0.59) | DYRK1APIK3CGPIK3CAMTOR | |
| SCHEMBL2065115 | 0.66 | PDE10A (0.37) | DYRK1AAHRPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | DYRK1A 1062/4885PIK3CG 7/4885AHR 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.